Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176878 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplant for Bone Marrow Failure Syndromes
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00176878 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 10 participants.
The verdict
NCT00176878, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.
Interventions
- DRUG Busulfan
- BIOLOGICAL anti-thymocyte globulin
- DRUG Fludarabine monophosphate
- PROCEDURE Total lymphoid irradiation
- PROCEDURE Stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2000-06 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176878
The ClinicalTrials.gov registry entry for NCT00176878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Busulfan is the first listed.
NCT00176878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176878 about?
NCT00176878 is a clinical study titled "Stem Cell Transplant for Bone Marrow Failure Syndromes". The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.
What is the current status of trial NCT00176878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2000-06. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00176878?
The interventions under investigation include: Busulfan (DRUG), anti-thymocyte globulin (BIOLOGICAL), Fludarabine monophosphate (DRUG), Total lymphoid irradiation (PROCEDURE), Stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00176878?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.